Skip to main content

View full-text article in PMC

. 2006 Jul 7;12(25):4061–4063. doi: 10.3748/wjg.v12.i25.4061

Table 1.

Change of HBV DNA in serum and PBMC of chronic hepatitis B patients after lamivudine treatment n (%)

	HBVDNA in serum				HBVDNA in PBMC
Group	4 wk	12 wk	24 wk	48 wk	Group	4 wk	12 wk	24 wk
Lamivudine Treatment 42	9 (21.1)	26 (61.9)^a	34 (80.9)^a	38 (90.5)^a	4 (9.5)	15 (35.7)^a	20 (47.6)^a	25 (59.5)^a
Routine Treatment 30	2 (6.7)	3 (10.0)	5 (16.7)	7 (23.3)	1 (3.3)	2 (6.7)	4 (13.3)	5 (16.7)

^a

P < 0.005 vs control group.